Healthcare provider profile · identity verified

Petr Slapnicka, MD

Internal Medicine · WENATCHEE, WA · NPI 1073532172

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	864	244
Amlodipine Besylate	Amlodipine Besylate	393	99
Omeprazole	Omeprazole	290	84
Lisinopril	Lisinopril	286	87
Losartan Potassium	Losartan Potassium	282	82
Levothyroxine Sodium	Levothyroxine Sodium	266	69
Metoprolol Succinate	Metoprolol Succinate	252	73
Tamsulosin Hcl	Tamsulosin Hcl	237	68
Potassium Chloride	Potassium Chloride	232	68
Simvastatin	Simvastatin	177	44
Metformin Hcl Er	Metformin Hcl	169	45
Rosuvastatin Calcium	Rosuvastatin Calcium	165	48
Gabapentin	Gabapentin	148	39
Hydrochlorothiazide	Hydrochlorothiazide	139	38
Allopurinol	Allopurinol	135	37
Trazodone Hcl	Trazodone Hcl	134	38
Glimepiride	Glimepiride	127	34
Furosemide	Furosemide	124	41
Ezetimibe	Ezetimibe	112	40
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	112	30
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	107	15
Atenolol	Atenolol	91	22
Metoprolol Tartrate	Metoprolol Tartrate	91	30
Finasteride	Finasteride	82	23
Tramadol Hcl	Tramadol Hcl	81	27
Clopidogrel	Clopidogrel Bisulfate	77	20
Trulicity	Dulaglutide	72	12
Oxycodone Hcl	Oxycodone Hcl	70	suppressed
Alendronate Sodium	Alendronate Sodium	69	19
Sertraline Hcl	Sertraline Hcl	67	16
Paroxetine Hcl	Paroxetine Hcl	66	15
Prednisone	Prednisone	63	19
Escitalopram Oxalate	Escitalopram Oxalate	62	14
Fluoxetine Hcl	Fluoxetine Hcl	62	13
Eliquis	Apixaban	60	22
Jardiance	Empagliflozin	59	16
Ozempic	Semaglutide	59	11
Labetalol Hcl	Labetalol Hcl	57	14
Montelukast Sodium	Montelukast Sodium	57	15
Venlafaxine Hcl Er	Venlafaxine Hcl	55	11
Albuterol Sulfate Hfa	Albuterol Sulfate	54	25
Metformin Hcl	Metformin Hcl	54	15
Pravastatin Sodium	Pravastatin Sodium	54	14
Lovastatin	Lovastatin	52	15
Amitriptyline Hcl	Amitriptyline Hcl	51	12
Digoxin	Digoxin	51	suppressed
Methocarbamol	Methocarbamol	51	19
Zolpidem Tartrate	Zolpidem Tartrate	50	14
Myrbetriq	Mirabegron	49	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	48	13
Fluticasone Propionate	Fluticasone Propionate	48	19
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	47	17
Pioglitazone Hcl	Pioglitazone Hcl	47	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	47	13
Donepezil Hcl	Donepezil Hcl	44	12
Carvedilol	Carvedilol	40	11
Citalopram Hbr	Citalopram Hydrobromide	40	15
Memantine Hcl	Memantine Hcl	36	suppressed
Estradiol	Estradiol	35	15
Bupropion Xl	Bupropion Hcl	34	11
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Benazepril Hcl	Benazepril Hcl	32	suppressed
Buspirone Hcl	Buspirone Hcl	32	suppressed
Mirtazapine	Mirtazapine	32	suppressed
Pregabalin	Pregabalin	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	11
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Glipizide Er	Glipizide	29	suppressed
Alprazolam	Alprazolam	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	suppressed
Nabumetone	Nabumetone	28	suppressed
Meloxicam	Meloxicam	27	suppressed
Lorazepam	Lorazepam	26	suppressed
Ipratropium Bromide	Ipratropium Bromide	25	suppressed
Celecoxib	Celecoxib	24	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Primidone	Primidone	24	suppressed
Propranolol Hcl Er	Propranolol Hcl	24	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	23	suppressed
Methylprednisolone	Methylprednisolone	22	20
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Verapamil Er	Verapamil Hcl	21	suppressed
Baclofen	Baclofen	20	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Nitroglycerin	Nitroglycerin	20	17
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Naproxen	Naproxen	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Risperidone	Risperidone	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	18	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	17	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Klor-Con M20	Potassium Chloride	16	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	suppressed
Temazepam	Temazepam	16	suppressed
Trospium Chloride	Trospium Chloride	16	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Aripiprazole	Aripiprazole	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	14	suppressed
Torsemide	Torsemide	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Premarin	Estrogens, Conjugated	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error